Mangoceuticals, Inc. (MGRX) company profile
Close on Nov 16, 2026Market cap $3.46MP/E –Yield –
About Mangoceuticals
Services-Misc Health & Allied Services, NEC, SIC 8090
Mangoceuticals, Inc. is a company that develops, markets, and sells men's health and wellness products and services, primarily focusing on telehealth and erectile dysfunction treatments. The company connects consumers with licensed healthcare professionals and partnered pharmacies to provide access to prescription and non-prescription wellness options. Its operations encompass several corporate subsidiaries and regional entities, including MangoRx Mexico and MangoRx UK Limited.
The company operates internationally with business interests and entities extending to Mexico and the United Kingdom. Its principal executive offices and headquarters are located in Dallas, Texas. Mangoceuticals conducts its primary administration and corporate management from its leased office premises within the state of Texas.
Summary of the business section of Mangoceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Mangoceuticals, Inc.
- Headquarters
- Dallas, TX
- Address
- 15110 Dallas Pkwy, Suite 600 75248
- Phone
- (833) 626-4679
- Website
- mangoceuticals.com
- Industry
- Services-Misc Health & Allied Services, NEC
- Incorporated in
- Texas
- Fiscal year ends
- December 31
- Auditor
- Turner, Stone & Company, L.L.P., Dallas, Texas
Stock & identifiers
- Ticker
- MGRX
- Exchange
- Nasdaq
- IPO date
- Mar 22, 2023
- Shares outstanding
- 22M, Aug 13, 2026
- Public float
- $14.73M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Stock splits
- 1-for-15 reverse, Oct 16, 2024
- SEC CIK
- 1938046
- CUSIP
- 56270V205
- ISIN
- US56270V2051
- FIGI
- BBG01CCMR9Q3
- Share class FIGI
- BBG01CCMRBK4
- LEI
- 984500BKBD93A8A67E98
- EIN
- 87-3841292
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jacob D. Cohen | Chief Executive Officer, Director | 11,305,000 |
| Antonios Isaac | President, Director | 60,000 |
| Eugene M. Johnston | CFO | 220,000 |
| Alex P. Hamilton | Director | 101,667 |
| Kenny Myers | Director | 136,667 |
| Lorraine Pamela D'Alessio | Director | 136,667 |
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Mar 22, 2023
- Offer price
- $4.00
- Securities offered
- 1,250,000
- Gross proceeds
- $5.00M
- Exchange
- Nasdaq
- First trading day
- Mar 21, 2023
- First-day close
- $4.00-0.0%
- Lock-up ends (est.)
- Sep 17, 2023
“The initial public offering price per share is $4.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
See a number that looks wrong?